We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-15.48%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$504M
AUM Growth
-$158M
Cap. Flow
-$56.6M
Cap. Flow %
-11.24%
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$10M
2
ALKS icon
Alkermes
ALKS
+$9.75M
3
ENDP
Endo International plc
ENDP
+$6.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.86M
5
GILD icon
Gilead Sciences
GILD
+$5.05M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$11.5M
2
MDT icon
Medtronic
MDT
+$8.44M
3
HNT
HEALTH NET INC
HNT
+$8.35M
4
ABMD
Abiomed Inc
ABMD
+$8.02M
5
CVS icon
CVS Health
CVS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 93.13%
2 Financials 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
76
DELISTED
Achillion Pharmaceuticals
ACHN
$2.05M 0.41%
266,000
– –
TNDM icon
77
Tandem Diabetes Care
TNDM
$1.56B
$1.82M 0.36%
20,900
– –
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$750M
$1.77M 0.35%
85,000
+569
+0.7% +$14K
ATXS
79
DELISTED
Astria Therapeutics
ATXS
$1.74M 0.35%
5,752
+648
+13% +$223K
ANTH
80
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.57M 0.31%
54,375
+23,125
+74% +$627K
ACAD icon
81
Acadia Pharmaceuticals
ACAD
$5.03B
$1.4M 0.28%
50,000
-70,000
-58% -$1.53M
TTPH
82
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.39M 0.28%
15,000
+3,750
+33% +$375K
RGLS
83
DELISTED
Regulus Therapeutics
RGLS
$1.39M 0.28%
1,667
– –
BHC icon
84
Bausch Health
BHC
$2.34B
$1.31M 0.26%
50,000
-19,000
-28% -$1.41M
NVRO
85
DELISTED
NEVRO CORP.
NVRO
$1.13M 0.22%
+20,000
New +$1.18M
ARRY
86
DELISTED
Array Biopharma Inc
ARRY
$1.09M 0.22%
370,000
– –
MRTX
87
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.07M 0.21%
50,000
– –
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$796K 0.16%
15,401
– –
OREX
89
DELISTED
Orexigen Therapeutics, Inc.
OREX
$675K 0.13%
120,000
+1,100
+0.9% +$14.3K
OCUL icon
90
Ocular Therapeutix
OCUL
$2.02B
$386K 0.08%
+40,000
New +$303K
BIND
91
DELISTED
BIND THERAPEUTICS INC
BIND
$294K 0.06%
133,535
– –
MTEM
92
DELISTED
Molecular Templates, Inc.
MTEM
$93K 0.02%
1,221
– –
BSX icon
93
Boston Scientific
BSX
$71.5B
– –
-274,000
Closed -$5.05M
CLDX icon
94
Celldex Therapeutics
CLDX
$3.28B
– –
-21,333
Closed -$5.02M
UHS icon
95
Universal Health Services
UHS
$10.5B
– –
-44,000
Closed -$5.26M
ICPT
96
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-26,000
Closed -$3.88M
RAD
97
DELISTED
Rite Aid Corporation
RAD
– –
-33,900
Closed -$5.32M
CLVS
98
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-73,000
Closed -$2.56M
TSRO
99
DELISTED
TESARO, Inc.
TSRO
– –
-50,899
Closed -$2.66M
SGNT
100
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-150,000
Closed -$2.39M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rhenman & Partners Asset Management held 102 positions worth $504M, down 24% from $661M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $56.6M in Q1 2016, closing 10 positions and reducing 33 holdings. Its most notable exit was HEALTH NET INC, an estimated $8.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Biogen worth $9.89M.

  • Rhenman & Partners Asset Management's largest Q1 2016 buy was Biogen: 38,000 shares worth $9.89M.
  • Rhenman & Partners Asset Management added most to Alkermes in Q1 2016, an estimated $9.75M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2016 reduction was Perrigo, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited HEALTH NET INC in Q1 2016, selling an estimated $8.35M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $504M portfolio in Q1 2016.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 10 in Q1 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $504M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.